Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5032MR)

This product GTTS-WQ5032MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Heloderma suspectum
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5032MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14886MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ5178MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ14448MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ1911MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AGN 150998
GTTS-WQ409MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ5347MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ13701MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ8718MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW